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AbstrACt
Introduction Perioperative infections may be considered 
predictors of caesarean scar defect (CSD), and multidose 
antibiotics have a protective effect against CSD. However, 
the ability of adjunctive azithromycin combined with 
cephalosporin to reduce the prevalence of CSD remains 
unclear. The planned study aims to clarify the protective 
effect of antibiotics against CSD and to assess the 
effectiveness of adjunctive azithromycin prophylaxis for 
CSD.
Methods and analysis This study is a double- blind, 
parallel- control randomised clinical trial that will be 
carried out at the International Peace Maternity and 
Child Health Hospital. A total of 220 eligible patients 
will be randomised (1:1) to receive either adjunctive 
azithromycin or single- dose cephalosporin 30 min before 
the incision. The evaluation criteria are the prevalence 
and characteristics of CSD as assessed by transvaginal 
ultrasound (TVU) and saline infusion sonohysterography 
(SIS) at 42 days, 6 months and 12 months after delivery. 
The primary outcome will be the prevalence of CSD, and 
the characteristics of CSD will be assessed by TVU and SIS 
42 days after delivery; all other outcomes are secondary.
Ethics and dissemination This protocol received 
authorisation from the Medical Research Ethics Committee 
of International Peace Maternity and Child Health Hospital 
on 25 April 2018 (approval no. GKLW2017-84). The 
findings will be reported in peer- reviewed publications and 
presentations at international scientific meetings.
trial registration number ChiCTR- INR-17013272.
IntroduCtIon
The rate of caesarean section (CS) delivery is 
increasing worldwide, especially in China due 
to the prevalence of maternally requested 
caesarean deliveries and the 30- year national 
one- child policy.1 According to the data from 
official figures of the China National Bureau 
of Statistics, there were approximately 
17 million newborns in China in 2017, with 
a caesarean delivery rate of approximately 
40%, which means that there are approxi-
mately 7 million CS deliveries each year.
There is no universally accepted definition 
or criterion for caesarean scar defect (CSD). 
In most studies, CSD is defined as ‘the thin-
ning of the myometrium or a triangular 
defect in the myometrium that is contiguous 
with the endometrial cavity’.2 It was stated in 
the research by Di Spiezio Sardo et al3 that 
remaining myometrial thickness (RMT) is 
defined as ‘the distance from the delineation 
of the endometrium to the serosal surface 
at the level of the caesarean scar, and total 
myometrial thickness was measured at the 
myometrium adjacent to the scar’, which 
refers to adjacent myometrium thickness 
(AMT). Some researchers have also indi-
cated that a niche should be described as 
strengths and limitations of this study
 ► This is the first interventional randomised controlled 
trial with the primary aims of assessing the protec-
tive effects of antibiotics against caesarean scar 
defect (CSD) and investigating the relationship be-
tween CSD occurrence and preoperative infection.
 ► This study is based on our previous cohort study, 
and we want to study the effects of infection and 
antibiotics on CSD directly.
 ► The study is a double- blinded randomised controlled 
trial with a relatively large sample size and a long 
follow- up period. In this set, we can find the optimal 
time point for the early detection of CSD.
 ► The trial is based in a single centre, which might 
limit the generalisability of the findings.
 ► This study is not a randomised controlled trial of 
different surgical techniques for uterine incision 
closure, which may be as or more important than 
antibiotics.
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the indentation of myometrium with a depth of at least 
2 mm.4 5 Additionally, according to Osser et al,6 a large 
CSD was defined as ‘thickness of the remaining myome-
trium over the defect ≤2.2 mm by TVU and ≤2.5 mm 
by SIS, ratio between the thickness of the remaining 
myometrium over the defect and the myometrial thick-
ness adjacent to the defect ≤23% by TVU and ≤29% by 
SIS for women who had undergone only one caesarean 
section’. Small CSDs may be definitely common and not 
considered significant. Nevertheless, large CSDs may lead 
to some long- term potential sequelae.7 In our study, we 
will focus on the differences in the prevalence rates and 
outcomes of CSDs and large CSDs. Data on measured 
parameters such as the height, length, width, RMT, AMT 
and niche volume of the CSD will be collected to present 
the characteristics of CSD.
In a random population of women with a history of 
CS, the prevalence of CSD ranges from 56% to 84% and 
24% to 70% when assessed by transvaginal ultrasound 
(TVU) with and without contrast enhancement, respec-
tively.8 Saline infusion sonohysterography (SIS) is better 
than traditional TVU for characterising CSD and has a 
higher sensitivity.9 Moreover, sonohysterography can 
more precisely evaluate the size and shape of the defect 
and thus the severity.10 In this study, we will apply and 
compare the differences between TVU and SIS.
CSD is associated with abnormal uterine bleeding 
(75% to 82%), postmenstrual spotting (29% to 34%), 
caesarean scar ectopic pregnancies (1:1800 to 1:2216) 
and infertility (32/92).4 11 12 Uterine dehiscence, uterine 
rupture, caesarean scar pregnancy and morbidly adherent 
placenta are also associated with CSD.13–15 Annually, there 
are thousands of fatalities and near- death cases caused by 
uterine rupture or haemorrhage from the CSD.16
Our previously published data first revealed a CSD 
prevalence of 43.4% (95% CI 39.1% to 47.7%, n=514) 
in Shanghai, which is a cause for concern.17 Our cohort 
study also showed that infection might be an important 
risk factor for CSD and that multidose antibiotic admin-
istration has a significant protective effect compared with 
single- dose antibiotic administration (CSD prevalence 
31.1%, 95% CI 23.8% to 38.3% vs 49.0%, 95% CI 43.8% to 
54.3%; aOR=0.4, 95% CI 0.3 to 0.7).18–20 Furthermore, the 
single- dose cefuroxime subgroup (n=190) was found to 
have a significantly lower CSD prevalence than the single- 
dose cefradine subgroup (n=162) (38.9%, 95% CI 34.7% 
to 48.6% vs 56.8%, 95% CI 51.3% to 66.7%; aOR=0.5, 
95% CI 0.3 to 0.8, p=0.006). These results strongly indi-
cate that antibiotics may be a protective factor for CSD.
According to the results of a study involving pathogen 
monitoring for nosocomial infections, Ureaplasma 
urealyticum, Escherichia coli, Enterococcus and Strep-
tococcus are the most common infectious agents.21 22 
Second- generation cephalosporins have a stronger anti-
bacterial effect against E. coli and Enterobacteriaceae than 
first- generation cephalosporin, while azithromycin has 
stronger antibacterial and bacteriostatic effects against 
atypical pathogens, such as Mycoplasma chlamydia and 
anaerobic bacteria.23 24 Current recommendations for 
antibiotic prophylaxis in caesarean delivery include the 
standard administration of a broad- spectrum antibi-
otic, most commonly a first- generation cephalosporin, 
before the skin incision.25 Recent reports on adjunctive 
azithromycin prophylaxis for caesarean delivery showed 
a significant protective effect against maternal endome-
tritis (3.8% vs 6.1%, p=0.02), wound infection (2.4% 
vs 6.6%, p<0.001) and serious maternal adverse events 
(1.5% vs 2.9%, p=0.03) but no significant between- 
group differences in secondary neonatal composite 
outcomes.26 In other words, the addition of azithromycin 
to caesarean delivery prophylaxis is less costly and leads 
to better maternal outcomes in index and subsequent 
deliveries.27–30
Therefore, we designed a prospective, randomised, 
double- blind, parallel- group study to determine whether 
the prophylactic use of cephalosporin plus azithromycin 
combination is superior to that of a single dose of ceph-
alosporin in reducing the prevalence of CSD. Our study 
has a strong theoretical basis and foundation, and this 
trial may provide evidence of the effective use of antibi-
otics in clinical practice and data indicating a reduction 
in the rate of CSD.
objective and hypothesis
The objective of this trial is to clarify the protective effects 
of antibiotics against CSD and to assess the effectiveness 
of adjunctive azithromycin prophylaxis for CSD. Our 
hypothesis is that the prophylactic use of cephalosporins 
combined with azithromycin is superior to a single dose 
of cephalosporin and can reduce the prevalence of CSD.
MEthods And AnAlysIs
study design and setting
The study design is that of a double- blind, parallel- 
control randomised clinical trial. Pregnant women 
with singleton pregnancies in cephalic presentation 
who have ruptured membranes or signs of labour will 
be informed about the study and the need to undergo 
CS by the medical team. The subjects will be randomly 
divided into two groups. The trial group (group A) will be 
administered the regular single- dose cefuroxime sodium 
(1.5 g/50 mL 0.9% sodium chloride (NaCl)) plus azith-
romycin (0.5 g/250 mL 0.9% NaCl). The control group 
(group B) will be administered the regular single- dose 
cefuroxime sodium (1.5 g/50 mL 0.9% NaCl) plus an 
additional placebo (250 mL 0.9% NaCl) as an intravenous 
drip 30 min before surgery. The prevalence and clinical 
symptoms of CSD at 6 weeks, 6 months, and 12 months 
after delivery will be observed with TVU and SIS. We 
will include 220 women in total. The primary outcome 
measure will be the prevalence of CSD, and the charac-
teristic of CSD will be assessed by TVU and SIS 42 days 
after delivery. The secondary outcome measures will be 
infection indexes and labour results, as shown in figure 1.
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Figure 1 Flowchart of the study. CS, caesarean section; 
TVUS, transvaginal ultrasonography.
Participants
Patients will be included in this study if they meet all the 
following criteria:
1. Han Chinese ethnicity with a maternal age of 18 years 
or older,
2. Singleton pregnancy with a gestational age ≥37 weeks,
3. Fibrinogen ≥2 g/L, platelet count ≥100×109 and hae-
moglobin ≥90 g/L before surgery,
4. Non- elective caesarean delivery during labour or after 
membrane rupture and
5. Labour defined as regular contractions with cervical 
dilation of 3 cm or with documented cervical changes 
of at least 1 cm of dilation or at least 50% effacement 
(women with membrane rupture for at least 4 hours 
will be eligible, regardless of whether labour has 
started).
Patients will be excluded from participating in the study 
if one of the following criteria is met:
1. The patient declines to participate in the trial,
2. The patient is known to be allergic to cefuroxime sodi-
um or azithromycin (including an allergy to any kind 
of macrolide or cephalosporin),
3. The patient was administered azithromycin within 7 
days before randomisation,
4. The patient is positive for Group B Streptococcus hae-
molyticus on screening at approximately 36 weeks.
5. The patient has a diagnosis of a non- reproductive tract 
infection (appendicitis, upper respiratory infection, 
urinary tract infection) and needs additional antibiot-
ic treatment,
6. The patient has a severe maternal disease (severe liv-
er or renal dysfunction, pulmonary oedema, cardiac 
structural abnormality or a condition requiring antiar-
rhythmic drug use, systematic lupus erythaematosus or 
inadequately controlled diabetes).
7. The patient has a stillbirth
8. The patient has a preoperative diagnosis of uterine ab-
normalities (such as uterine malformation, adenomyo-
sis or myoma of the uterus) or
9. The patient has undergone a previous CS.
randomisation
Demographic, medical and obstetrical information 
will be collected at baseline. The patient will then be 
randomised between the trial group (group A) and the 
control group (group B) according to her serial number 
(number 1 to 250, depending on the time of trial entry). 
The randomisation codes will be generated by the block 
of the statistical software at a 1:1 ratio (SPSS, V.22.0, IBM, 
Armonk, New York, USA). We will generate a list of 250 
randomisation codes (A or B). Each code will correspond 
to one serial number, and each code will be placed in a 
black envelope with the serial number printed on the 
outside. Anyone who will have contact with the patient 
or other researchers will be blinded to the list. Antibiotic 
prophylaxis will be administered within 30 min before 
incision. The medicine will be dissolved in the hospital 
dispensary, where the patient’s envelope will be opened 
by an independent pharmacist, and the containers will 
be identical so that no one else can identify the set. The 
opened envelope will be locked in a non- transparent box 
until the trial is finished. These settings will ensure that 
both the participants and investigators or surgeons are 
blinded to the treatment.
Intervention
All participants will undergo a standard CS with a lower 
segment uterine incision and double- layer suturing of 
the uterine wound. The first layer will be the decidua 
and total myometrium, and the second layer will be 
the serosa and the upper half layer of myometrium. All 
sutures will be continuously unlocked with absorbable 
suture material. We have three experienced surgeons 
with the same technical standards who will be respon-
sible for the trial. Each of them will perform approxi-
mately 70 CSs randomly in the trial. All the participants 
will be cared for in the wards, and additional antibiotics 
will be given if there is a confirmed infection before the 
patient checks out.
Withdrawal of participants
The participants will be able to leave the study at any time 
for any reason if they wish to do so, without any conse-
quences. The investigator will be able to decide to with-
draw a subject from the study for urgent medical reasons. 
After randomisation, if a woman wishes to change her 
assigned protocol, she will be considered a crossover 
subject. All subjects will remain in the study for analysis 
based on the intention- to- treat principle.
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Table 1 Patient's characteristics and data collection
Data collection
Days
BL 0 1 2 3 4 42 6 months 12 months
Age ×                 
BMI ×                 
Gestational age ×                 
Screen ×                 
Informed consent ×                 
Randomisation ×                 
TVU             × × ×
SIS             × × ×
Antibiotics × ×               
Blood infection index ×   ×             
Blood coagulation function ×   ×             
Secretion culture × ×         ×     
Temperature × × × × × ×       
The skin infection of incision   × × × × ×       
Endometritis   × × × × ×       
Puerperal fever   × × × × ×       
Other postoperative complications   ×               
Questionnaire             × × ×
BL, baseline; BMI, body mass index; TVU, transvaginal ultrasound; SIS, saline infusion sonohysterography.
Participant timeline
The schedules for enrolment, interventions and assess-
ments are summarised in table 1.
The CS will be performed on day 0, and antibiotic treat-
ment, which will be randomly assigned, will be started on 
day 1.
All included patients will undergo randomisation and 
treatment. We will conduct preoperative and postoper-
ative routine blood tests and detect C- reactive protein 
(CRP) levels, procalcitonin (PCT) levels and blood coag-
ulation function. We will also culture vaginal secretions 
before surgery and at 42 days postpartum.
Clinical evaluations of the efficacy and safety of anti- 
infection prophylaxis will be performed during hospital-
isation and will include evaluations of the incidence of 
puerperal fever, skin infections at the incision site, endo-
metritis and other postoperative complications.
Clinical symptoms as well as the prevalence and charac-
teristics of CSD at 6 weeks, 6 months and 12 months after 
caesarean delivery will be documented.
Primary outcome measure
The prevalence of CSD, and the characteristic of CSD will 
be assessed by TVU and SIS 42 days after delivery.
secondary outcome measure
1. The changes in infection indexes, such as routine 
blood examinations including CRP and PCT before 
and after surgery.
2. Presurgical vaginal secretion culture results and intra-
operative uterine cavity culture results.
3. Body temperature 6 hours before and 72 hours after CS.
4. Postoperative morbidity, endometritis and incisional 
infection after surgery and severe infection 42 days af-
ter delivery.
5. Type and dosage of all antibiotics administered postop-
eratively according to standard processes.
6. Responses to postpartum questionnaires at approxi-
mately 6 weeks, 6 months and 12 months.
7. Follow- up data from TVU and SIS evaluations per-
formed at 6 months and 12 months after delivery.
8. The size and position of the uterus and the height, 




Based on the findings of previous studies, we concluded 
that the occurrence of CSD decreases from 47.9% to 29% 
after the administration of multidose antibiotics during 
emergency caesarean delivery. We will predict the occur-
rence of CSD after using two prophylactic antibiotics with 
PASS sample prediction software V.11.0. We will need to 
include 220 women in total (two groups of 110 women), 
with an alpha error of 0.05. Assuming a 10% dropout 
rate, we will need to randomise a total of 242 participants 
(121 participants per group).
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statistical analysis
For analysis, the adopted Electronic Data 
Capture（EDC）c system will be used to collect data 
uniformly and record all relevant personal information 
for data collection points. The method of automatic 
computer verification, which will include data that clearly 
do not conform to the conventional standards and among 
which values are missing, will be adopted. Researchers will 
be required to check the original data, and all changes in 
the data will be managed with traces. Query tables will be 
checked if necessary.
For the analysis of the data, t- tests, analysis of variance, 
χ2 tests and other differential tests will be carried out with 
SPSS software.
Descriptive statistics will be used to analyse demo-
graphic data and laboratory indicators, such as basic 
information from the preoperative period, from the 
postoperative hospitalisation period and at 6 weeks post- 
surgery. Preoperative and postoperative indicators will be 
used for baseline data, and the normality of the distribu-
tion of continuous variables from the baseline data will be 
tested. Normally distributed data will be reported as the 
mean and SD, and the two groups will be assessed by the 
independent samples t- test; if the data are non- normally 
distributed, a non- parametric analysis will be performed, 
and the data will be reported as the median and IQR. We 
will use the χ2 test or Fisher’s exact test to analyse categor-
ical variables.
We will apply the χ2 test to assess the primary outcome 
to compare the occurrence rate of the CSD in two groups.
We will apply the t- test, analysis of variance and χ2 test 
to evaluate the secondary outcome according to the char-
acteristics of the endpoint.
Patient and public involvement
Neither the patients nor the public will be involved in the 
study design. They will also not be involved in the recruit-
ment process or conduct of the study. The results will be 
disseminated to patients via an open access publication 
and our local trials teams.
dIsCussIon
Since the mechanism of wound healing in uterine 
caesarean incisions is not fully known and since the natural 
development of CSD over time is still unclear, uterine 
scars and CSD may change over time. One prospective 
observational study showed that CSD occurred from 
6 weeks to 6 months or longer after surgery.30 Another 
prospective study reported that the statuses of some 
women with or without CSD showed a reversal between 6 
weeks and 6 months after surgery (90.7% at 6 weeks and 
93.1% at 6 months (OR 0.96 (0.61 to 1.49), p=0.91)).31 
This trial is based on our previous cohort study in which 
CSD was observed at 6 weeks postpartum. We will set the 
initial CSD assessment time point as 6 weeks postpartum 
and follow patients for 1 year, aiming to find the optimal 
time point for the early detection of CSD. Our sample 
size calculation is also based on previously published data, 
which were based on the measurement of CSD with TVU 
and may have resulted in an underestimation.16 Since we 
believe that the difference between the two groups will 
be more significant when CSD is measured with SIS, the 
sample size could be large enough to observe a differ-
ence. We believe that surgical techniques of uterine inci-
sion and closure may be important in the occurrence of 
CSD, and there are many trials that are ongoing or that 
already have results.32 33 We will focus on the effects of 
infection and antibiotics against CSD based on the strong 
indication of our previous study.
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